Skip to main content

Lexiva and Alcohol/Food Interactions

There are 2 alcohol/food/lifestyle interactions with Lexiva (fosamprenavir).

Moderate

Fosamprenavir Food

Moderate Food Interaction

ADJUST DOSING INTERVAL: Food may reduce the systemic bioavailability of amprenavir from fosamprenavir oral suspension. The mechanism of interaction has not been described. According to the product labeling, administration of fosamprenavir oral suspension (1400 mg single dose) with a high-fat meal (967 kcal, 67 g fat, 33 g protein, 58 g carbohydrate) reduced amprenavir peak plasma concentration (Cmax) by 46% and systemic exposure (AUC) by 28% compared to administration in a fasted state. The time to reach peak plasma level (Tmax) was delayed by 0.72 hours. In contrast, the same high-fat meal did not affect the pharmacokinetics of amprenavir from fosamprenavir tablets.

MANAGEMENT: Fosamprenavir suspension should be administered on an empty stomach in adults, but with food in pediatric patients to aid palatability and compliance. If emesis occurs within 30 minutes after dosing the suspension, the dose should be repeated. Fosamprenavir tablets may be taken with or without food.

References

  1. (2003) "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline

Switch to consumer interaction data

Moderate

Fosamprenavir High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)

Moderate Potential Hazard, Moderate plausibility

PIs - hyperlipidemia

Treatment with ritonavir alone or in combination with other protease inhibitors (e.g., lopinavir, saquinavir, tipranavir, fosamprenavir) has resulted in substantial increases in the concentration of total cholesterol and triglycerides. These effects have also been reported with other protease inhibitors but may be the most dramatic with ritonavir. The clinical significance of these elevations is unclear. Marked elevation in triglyceride levels is a risk factor for development of pancreatitis. Triglyceride and cholesterol testing is recommended before starting ritonavir (with or without other protease inhibitors) and periodically during therapy. Lipid disorders should be managed as clinically appropriate.

References

  1. (2022) "Product Information. Norvir (ritonavir)." AbbVie US LLC, SUPPL-25
  2. (2020) "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, SUPPL-44
  3. (2019) "Product Information. Lexiva (fosamprenavir)." ViiV Healthcare, SUPPL-41
  4. (2020) "Product Information. Kaletra (lopinavir-ritonavir)." AbbVie US LLC, SUPPL-54
  5. (2020) "Product Information. Invirase (saquinavir)." Roche Laboratories, SUPPL-25
  6. (2020) "Product Information. Aptivus (tipranavir)." Boehringer Ingelheim, SUPPL-21
View all 6 references

Lexiva drug interactions

There are 486 drug interactions with Lexiva (fosamprenavir).

Lexiva disease interactions

There are 4 disease interactions with Lexiva (fosamprenavir) which include:

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer